Abstract
Introduction

1
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis largely due to its propensity for 2 early local invasion, distant metastasis and lack of effective therapies. Many chemotherapeutic 3 regimens have failed and the current standard-of-care therapy, gemcitabine (GEM), extends 4 patient survival by only a few months (1) . Newer treatment options for PDAC patients are 5 FOLFIRINOX and nab-paclitaxel/GEM, which improved overall survival by 4.3 and 1.8 months 6 over GEM therapy, respectively (2, 3). However, safety profile of these drugs is less favorable 7 than GEM therapy, accounting for myelosuppression and peripheral neuropathy (2-4). Despite 8 these advances, the overall outcome remains miserable for this patient population. Thus, 9 investigations on alternative approaches for PDAC therapy are a high research priority.
10
Activation of oncogenes such as Kras and/or inactivating mutations or loss of expression of 11 tumor suppressor genes (including DPC4, p16, p53, and SMAD4) is known in PDAC (5) . It has 12 been shown that extensive desmoplasia is one of the underlying causes of pancreatic cancer's 13 poor prognosis and chemoresistance (6) . Desmoplasia is typically characterized by excessive 14 production of extracellular matrix (ECM) and collagen I and is associated with proliferation of 15 stromal cells, myofibroblasts and pancreatic stellate cells. A profound role of Sonic hedgehog 16 (SHH) pathway is implicated in desmoplasia (7) and cancer progression (8), including PDAC 17 (9). This developmental pathway, dormant in the adult pancreas, becomes reactivated early in 18 PDAC development (13). SHH is a member of the Hedgehog (Hh) family of secreted signaling 19 proteins, having diverse functions during vertebrate development (10) . In pancreatic tumors, 20 intimate reciprocal interactions occur between epithelia and underlying stroma due to paracrine 21 Hh signaling that lead to desmoplasia and form a barrier to chemotherapy drug(s) penetration progression signaling pathways with no or minimal adverse effects is required.
Repurposing of established drugs as anti-cancer agents is a current active investigative approach.
11
Ormeloxifene (ORM) is a non-hormonal, non-steroidal oral contraceptive molecule (18) . Recent 12 studies suggested that ORM may be effective in inhibiting breast cancer, head and neck cancer, 13 and chronic myeloid leukemia cells (18) . Moreover, ORM is reported to have an excellent 14 therapeutic index and is safe for chronic administration (19). This study demonstrates the 15 inhibitory role of ORM on the SHH signaling pathway, and describes inhibitory patterns of this 16 drug on pancreatic tumor progression using bidirectional tumor stromal interactions. This 17 inhibitory effect was either more pronounced or comparable to a known SMO inhibitor, GDC- Further, the combinatorial effects of ORM with GEM induce increased GEM sensitivity.
21
Additionally, these studies also suggest wide use of ORM in PDAC patients due to its intended (South Dakota State University) as described earlier (23) . GEM was purchased from Sigma 10 Aldrich (catalog number G6423) and GDC-0449 from Sellekchem (catalog number S1082).
11
Cells were treated with indicated doses of ORM, GEM and GDC-0449 after completely 12 solubilized in ethanol, PBS and DMSO, respectively.
13
Cell proliferation by MTS assay
14
The anti-proliferative effect of ORM was determined after 48 hours using the CellTiter 96 AQ eous
15
One solution assay (catalog number G5421, Promega) using a microplate reader (BioMate 3 UV-
16
Vis spectrophotometer, Thermo Electron Corporation). Ethanol-or PBS-containing medium 17 served as the vehicle control. Additionally, the anti-proliferative effect of ORM was determined 
Flow cytometric analysis of apoptosis and necrosis
9
BxPC-3 and Panc-1 cells (1 x 10 6 ) were treated for 24 hours with ORM (15 µM) and GEM (100 10 nM) alone and in combination. Cells were stained with Annexin V-FITC and propidium iodide 11 (PI). The apoptotic and necrotic populations were detected as described earlier (25). Cells were 12 scanned in FL-1 (FITC) versus FL-2 (PI) channels and analyzed using an Accuri C6 flow 13 cytometer (Accuri Cytometers, Inc.).
14
Cell cycle analysis
15
Cells were exposed to ORM (15 µM) and GEM (100 nM) alone or in combination for 24 hours 16 and stained with Telford Reagent containing propidium iodide (catalog number P-4170, Sigma 17 Aldrich). Cells were analyzed with an Accuri C6 flow cytometer. Cells with hypodiploid DNA
18
(content less than G0-G1) were deemed apoptotic (sub-G 0 /G 1 ). Scientific) and the percent of colonies was calculated as compared to control, as described earlier 4 (28).
5
Cell motility, migration and invasion assays 6 Cell motility was analyzed with a Boyden's chamber assay (28). For cell invasion assays, BD Human PDAC cells (1x10 6 ) were treated with ORM (15 µM) and GEM (100 nM) alone 1 and in combination for 24 hours. Total cell lysates were prepared followed by immunoblotting 2 for various indicated proteins as described earlier (25).
3
Reverse transcription-quantitative real-time polymerase chain reaction (Q-RT-PCR) 4 Total RNA was extracted using TRIZOL reagent (catalog number AM 9738, Invitrogen) and were allowed to grow for 7 days in 0.5% serum free medium (Cellprogen) to form primary 13 spheres. Following the incubation, the primary spheres were dissociated into single cell 14 suspension and plated at a density of 1×10 4 /2 ml/6 well ultra-low attachment plate. Secondary 15 spheres were counted after 7 to 10 days in culture.
17
In vivo tumor xenograft model 18 Six-week-old female athymic nude (nu/nu) mice were purchased from Charles River
19
Laboratories International, Inc., and maintained in a pathogen-free environment. The mice were an analysis of variance approach. Tests of main effects (differences between treatments) and 13 contrasts were performed.
14
Results
15
ORM treatment suppresses tumorigenic features of PDAC cells 16 ORM was found to have an anti-cancer effect on all tested PDAC cells ( Fig. 1A and S1A). To 17 confirm these results, we measured the growth in real time for duration of 100 hours using the 18 xCELLigence System (Fig. 1B) . This assay monitors cell growth in real time by measuring The growth curve, which is presented as a baseline cell index, showed that ORM significantly 4 reduced the baseline cell index compared to the control cells (Fig. 1B) . Further, ORM treatment 5 inhibited the clonogenic potential of PDAC cells (BxPC-3, Panc-1, AsPC-1, MiaPaca and 6 HPAF-II) as evident by the decreased number of colonies after ORM treatment (Fig. 1C) . Moreover, ORM was also found to inhibit cellular motility ( (Fig. S1C) , which was further 10 confirmed using the xCELLigence method (Fig. 2C) . ORM treatment inhibits tumorsphere formation in pancreatic stem cells 18 We observed a significant effect of ORM on tumorsphere formation in CSCs as reflected by a 19 reduction in size and number of tumorspheres in cells upon treatment suggesting the clonogenic 20 depletion of the CSCs. In contrast, GDC-0449 did not show a significant effect on secondary 21 tumorsphere formation (Fig. S2D) . ORM inhibits SHH signaling in PDAC cells 1 The SHH signaling pathway has been implicated in the development of pancreatic cancer (9). expression at protein and mRNA levels at indicated concentrations ( Fig. 2D and S3A and B).
5
ORM treatment also inhibited the expression of Gli-1, SMO, cyclin D1 and p-AKT, the key 6 downstream proteins that drive the oncogenic signaling of SHH signaling pathway in BxPC-3 7 and MiaPaca cells (11) (Fig. 2D and S3A ). ORM treatment also increased the expression of 8 tumor suppressor SUFU, which interacts directly with Gli-1 proteins to repress SHH signaling 9 (32) ( Fig. 2D and S3A ). Fig. 2D and S3C ). Cyclin D1 is the important mediator of SHH-induced cell proliferation and 13 carcinogenesis. These data suggest that ORM treatment effectively inhibits tumorigenic 14 phenotypes via modulation of SHH and its downstream signaling molecules.
15
ORM and GEM in combination induce apoptosis in PDAC cells 16 We investigated if ORM treatment enhanced the apoptotic index in GEM-resistant PDAC cells 17 (Panc-1 and BxPC-3). Our data show that when combined, ORM (15 µM) and GEM (100 nM) 18 induced a significantly higher (21%) apoptotic population in 24 hours as compared to ORM and 19 GEM treatment alone (Fig. 3A) . However, PI-positive post-apoptotic/necrotic cell population effects on the expression of SHH, Gli-1 and SMO as compared to ORM or GEM alone (Fig. 3D) .
18
This reveals the potentiated effects of ORM in combination with GEM. We also confirmed these 
(PTCH1/2) compared to the control (Fig. 3C) . ORM alone or in combination with GEM also 1 showed a marked (~40%) decrease in the level of anti-apoptotic, Bcl-xL protein (Fig. 3D) . The 2 Bcl-xL protein is also an important mediator of SHH and is transcriptionally regulated by SHH 3 through the Gli-1 transcription factor (34). Additionally, ORM alone or in combination with 4 GEM inhibited the Gli-1 and NFκB-65 transcriptional activity in PDAC cells (Fig. 4A and S3C ).
5
These results present first evidence that ORM inhibits the SHH-Gli-1 signaling pathway in 6 PDAC.
7
Moreover, we evaluated the ability of ORM and GEM to inhibit tumor progression and found 8 that ORM inhibited motility (Fig. 4B ) and the migratory ability of PDAC cells as demonstrated 9 by wound healing (Fig. 4C) . which the PDAC cells were cultured (Fig. 4D) . CXCL12 is abundantly produced by the stromal 
Combined ORM and GEM treatment effectively inhibits tumor burden in mice model
9
To investigate the anti-cancer effects of ORM, we used a subcutaneous (for solid tumor) and (Fig. 5B) . Moreover, in the intraperitoneal model, tumors barely developed in the ORM+GEM 16 treated group. Upon further examination, we also found there were fewer or no metastases in the 17 mice treated with ORM alone or in combination with GEM (Fig. 5B, inset table) . miR-132 is 18 downregulated in pancreatic cancer, which contributes to pancreatic cancer development (39).
19
Treatment of ORM alone or in combination with GEM leads to increased levels of miR-132 in 20 xenograft tumors (Fig. 5C ). This data further confirms that ORM treatment along with GEM 21 could be an effective therapeutic modality for pancreatic cancer. (Fig. 5D) . In contrast to vehicle or GEM treated mice, which exhibited 6 profuse desmoplastic tumor stroma, mice treated with ORM showed markedly depleted 7 desmoplastic stroma. This was evidenced by a decrease in collagen I content in tumor xenografts 8 and the invading host mice cells migrating into the tumors (Fig. 6A) . It was found that only 9 ORM, but not GEM, reduced the amount of collagen I deposition. Interestingly, these differences (Fig. 6B) . Further, we analyzed these tumor tissues for the presence of Experimental investigations indicate that ORM inhibits proliferation, invasion and clonogenicity 2 of PDAC cells ( Fig. 1 and Fig. S2 ), comparable to cells treated with GDC-0449. Additionally, No such effects were found in cells when treated with GEM alone. In the absence of SHH, cells 21 have small amounts of PTCH1/2 and Gli and therefore, the high concentrations of these relationship between these two components, leading to reduction of tumor progression, invasion, 10 metastasis and chemoresistance (Fig. 7) . This facilitates the anti-cancer effects of ORM and 
